Compugen (CGEN) Research & Development (2009 - 2026)
Compugen (CGEN) posted quarterly Research & Development of $6.9 million for Q1 2026, up 20.16% year-over-year from $5.8 million in Q1 2025, and up 25.15% on a QoQ basis from $5.5 million in Q4 2025.
Compugen (CGEN) Research & Development (2009 - 2026) Analysis & Trends
Compugen has reported Research & Development for 18 years, with the latest figure at $6.9 million in Q1 2026.
- Research & Development for Q1 2026 came in at $6.9 million, up 20.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.9 million (down 1.04% YoY), and the FY2025 annual result was $22.8 million, down 8.27% from the prior year.
- Research & Development rose to $6.9 million in Q1 2026, from $5.5 million in the prior quarter.
- Over five years, Research & Development peaked at $10.9 million in Q4 2023 and troughed at -$6.7 million in Q2 2022.
- A 5-year average of $6.2 million and a median of $6.4 million in 2024 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development slumped 198.46%; it then jumped 215.97% in 2023.
- A 5-year view of Research & Development shows it stood at $7.3 million in 2022, then jumped by 49.15% to $10.9 million in 2023, then tumbled by 45.91% to $5.9 million in 2024, then dropped by 6.23% to $5.5 million in 2025, then rose by 25.15% to $6.9 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $6.9 million in Q1 2026, $5.5 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 | 6.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.94 Mn |
| Dec 31, 2025 | 5.54 Mn |
| Sep 30, 2025 | 5.80 Mn |
| Jun 30, 2025 | 5.64 Mn |
| Mar 31, 2025 | 5.77 Mn |
| Dec 31, 2024 | 5.91 Mn |
| Sep 30, 2024 | 6.31 Mn |
| Jun 30, 2024 | 6.18 Mn |
| Mar 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 10.93 Mn |
| Sep 30, 2023 | 8.34 Mn |
| Jun 30, 2023 | 7.76 Mn |
| Mar 31, 2023 | 7.45 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 9.34 Mn |
| Jun 30, 2022 | -6.69 Mn |
| Mar 31, 2022 | 7.17 Mn |
| Dec 31, 2021 | 5.84 Mn |
| Sep 30, 2021 | 8.73 Mn |
| Jun 30, 2021 | 6.80 Mn |